← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
226	226 Redhill Biopharma RDHL $4.48M	14	-2	-13%	$270K
227	227 Purple Biotech PPBT $2.07M	13	-2	-13%	$141K
228	228 HCW Biologics HCWB $2.75M	12	-1	-8%	$516K
229	229 Processa Pharmaceuticals PCSA $4.66M	12	+2	+20%	$498K
230	230 CNS Pharmaceuticals CNSP $7.57M	11	-1	-8%	$1.34M
231	231 Eocene Ltd. Ordinary Shares EOCN $3.12M	11	-2	-15%	$85.9K
232	VBIO 232 Valion Bio VBIO $1.12M	11	+3	+38%	$206K
233	233 Innate Pharma IPHA $166M	10	+1	+11%	$354K
234	234 NuCana NCNA $4.29M	10	+2	+25%	$168K
235	235 Akari Therapeutics AKTX $19.1M	9	+3	+50%	$1.54M
236	236 Aptevo Therapeutics APVO $3.11M	9	0	0%	$224K
237	237 Eterna Therapeutics ERNA $2.39M	9	-6	-40%	$236K
238	238 Genenta Science GNTA $32.5M	9	-2	-18%	$1.33M
239	239 Indaptus Therapeutics INDP $353M	9	+3	+50%	$1.15M
240	SLBT 240 SL Science Holding Ltd SLBT $981M	9	+9	–	$2.78M
241	241 Ascentage Pharma AAPG $1.36B	8	+1	+14%	$264K
242	242 Biodexa Pharmaceuticals BDRX $467K	8	+1	+14%	$48.1K
243	243 Can-Fite BioPharma American Depositary Shares CANF $4.03M	8	-6	-43%	$149K
244	244 TransCode Therapeutics RNAZ $30.5M	8	0	0%	$208K
245	VRXA 245 Veraxa Biotech AG VRXA $153M	8	+8	–	$600K
246	246 Xenetic Biosciences XBIO $4.52M	8	+2	+33%	$443K
247	247 Nexentis Technologies NXTS $945K	6	-2	-25%	$272K
248	248 Radiopharm Theranostics RADX $16.2M	6	-1	-14%	$1.18M
249	249 Silexion Therapeutics SLXN $2.62M	6	-1	-14%	$42.5K
250	250 DELISTED Aptorum Group APM	5	-3	-38%	$74.2K